Meda licenses Sublinox, OX-NLA from Orexo

Orexo (SSE:ORX) granted Meda (SSE:MEDA) exclusive, worldwide rights to market Sublinox and OX-NLA. Sublinox, a sublingual, mucoadhesive zolpidem tablet, has completed Phase III testing in insomnia, with an NDA submission expected this quarter. OX-NLA is a nasal spray of nitric oxide-donating derivative of antihistamine cetirizine that has completed Phase II testing for non-allergic and allergic rhinitis. ...